Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression
出版年份 2016 全文链接
标题
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 44, Pages 12508-12513
出版商
Proceedings of the National Academy of Sciences
发表日期
2016-10-05
DOI
10.1073/pnas.1605336113
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model
- (2016) Mariya Moosajee et al. HUMAN MOLECULAR GENETICS
- Rules of UGA-N decoding by near-cognate tRNAs and analysis of readthrough on short uORFs in yeast
- (2016) Petra Beznosková et al. RNA
- Translational readthrough-promoting drugs enhance pseudoknot-mediated suppression of the stop codon at the Moloney murine leukemia virus gag–pol junction
- (2015) Lisa Green et al. JOURNAL OF GENERAL VIROLOGY
- European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene
- (2015) Manuel Haas et al. NEUROMUSCULAR DISORDERS
- Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3
- (2015) Bijoyita Roy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutics Based on Stop Codon Readthrough
- (2014) Kim M. Keeling et al. Annual Review of Genomics and Human Genetics
- Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay
- (2014) Laura Lentini et al. MOLECULAR PHARMACEUTICS
- Ataluren treatment of patients with nonsense mutation dystrophinopathy
- (2014) Katharine Bushby et al. MUSCLE & NERVE
- New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae
- (2014) Sandra Blanchet et al. NUCLEIC ACIDS RESEARCH
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Eitan Kerem et al. Lancet Respiratory Medicine
- Correction of NonsenseBMPR2andSMAD9Mutations by Ataluren in Pulmonary Arterial Hypertension
- (2013) Kylie M. Drake et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor
- (2013) Xiaojiao Xue et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment
- (2013) Mei Li et al. FASEB JOURNAL
- New structural insights into the decoding mechanism: Translation infidelity via a G·U pair with Watson-Crick geometry
- (2013) Natalia Demeshkina et al. FEBS LETTERS
- Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects
- (2013) Cheryl Y. Gregory-Evans et al. JOURNAL OF CLINICAL INVESTIGATION
- Premature Termination Codon Read-Through in the ABCC6 Gene: Potential Treatment for Pseudoxanthoma Elasticum
- (2013) Yong Zhou et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
- (2013) Richard S. Finkel et al. PLoS One
- A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
- (2013) Stuart P. McElroy et al. PLOS BIOLOGY
- Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate
- (2012) Mary P. Hall et al. ACS Chemical Biology
- Ataluren as an Agent for Therapeutic Nonsense Suppression
- (2012) Stuart W. Peltz et al. Annual Review of Medicine
- Structure-Activity Relationships among the Kanamycin Aminoglycosides: Role of Ring I Hydroxyl and Amino Groups
- (2012) Sumantha Salian et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia
- (2012) Rocío Sánchez-Alcudia et al. HUMAN MUTATION
- PTC124-Mediated Translational Readthrough of a Nonsense Mutation Causing Usher Syndrome Type 1C
- (2011) T. Goldmann et al. HUMAN GENE THERAPY
- Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
- (2010) Isabelle Sermet-Gaudelus et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- An Evolutionarily Conserved Mechanism for Controlling the Efficiency of Protein Translation
- (2010) Tamir Tuller et al. CELL
- Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124
- (2010) D. S. Auld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Upf1 stimulates degradation of the product derived from aberrant messenger RNA containing a specific nonsense mutation by the proteasome
- (2009) Kazushige Kuroha et al. EMBO REPORTS
- Nonsense suppression activity of PTC124 (ataluren)
- (2009) S. W. Peltz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression
- (2009) D. S. Auld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
- (2008) Eitan Kerem et al. LANCET
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
- (2008) M. Du et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now